Journal
CLINICAL LYMPHOMA & MYELOMA
Volume 6, Issue 6, Pages 496-499Publisher
CIG MEDIA GROUP, LP
DOI: 10.3816/CLM.2006.n.033
Keywords
B-cell lymphoma; CD20; chemotherapy; rituximab; splenectomy
Categories
Ask authors/readers for more resources
We describe the case of a 61-year-old patient with refractory splenic marginal zone lymphoma and secondary autoimmune hemolytic anemia, both successfully treated with rituximab. This case demonstrates that rituximab monotherapy might also be a valid therapeutic approach in marginal zone lymphoma and autoimmune hemolytic anemia after failure of first-line treatment. Maintenance therapy, although expensive, could be useful to improve event-free survival in patients with unfavorable clinical behavior.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available